Dr Reddy’s News: The Delhi High Court has banned the sale of Dr. Reddy’s Laboratories and Vancorce Specialty Pharma in India. This is the active ingredient of Novo Nordisk’s weight loss drug VEGOVY. According to a CNBC-TV18 report, the Delhi High Court has issued this interim order after hearing a patent violation case filed by Denmark’s Pharma Company Novo Nordisk. This decision has come in such an important time when the demand for treatment of obesity and sugar is increasing worldwide and Novo Nordisk is preparing to launch the drug Vigovi connected to it in India.
How big is the market of obesity related to obesity in India?
The market for obesity holding medicines is increasing at the speed of rocket in India. It increased four times in four years. According to Pharmatrac’s data, it rose from ₹ 133 crore to ₹ 576 crore in March 2022. One of the reasons for this is Semaglutide, whose market value is ₹ 397 crore, which is much higher than its rivals Liraglutide and Dulaglutide.
Novo Nordisk’s Big Plan
The demand for obesity medicine in India is increasing rapidly. Due to this, Novo Nordisk has changed its strategy. Earlier it was to launch Vigovi in the year 2026 but now the pharma company has increased its launch speed. The company’s decision to bring Vigovi into the market soon has recently come after Mounjaro’s entry into the Indian market, which has come to the Indian market, after which the competition has increased in the market. For this reason, Novo Nordisk had to change the strategy to maintain its position in the market. Talking to Moneycontrol, the company said that as a healthcare company, it considers the responsibility of ensuring the availability of treatment for its patients.
Park Hotels Share Price: Not booked 51% profit, now IPO investors in two and a half percent losses, what shares will be recovering?
